PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT Data Transcript

PresentationI would now like to hand the conference call over to Laurence Watts of New Street Investor Relations. Please go ahead.Welcome to the PepGen conference call to discuss top line results from lowest dose MAD cohort in the Phase II FREEDOM2 study, demonstrating promising safety, splicing and vHOT data. [Operator Instructions] As a reminder, this call is being recorded today, Monday, March 30, 2026.Laurence Watts Thank you, operator. Joining us on the call today from PepGen are President and Chief Ex ...